ライフサイエンスコーパス: prosthesis

1 lacement and loss of retention of his ocular prosthesis.

2 dical Products Inc, California, USA) retinal prosthesis.

3 a random, scattered signal presented to the prosthesis.

4 ps, stroke than did recipients of a biologic prosthesis.

5 ng movements from ECoG to control a grasping prosthesis.

6 amputation improved control of a robotic leg prosthesis.

7 traction and the placement of the definitive prosthesis.

8 val does not differ with tissue or nontissue prosthesis.

9 the exchange of removable components of the prosthesis.

10 d therapeutic potential for use in a retinal prosthesis.

11 used to approximate walking with a compliant prosthesis.

12 ally loaded with a screw-retained definitive prosthesis.

13 ronic antibiotic suppression to preserve the prosthesis.

14 d a chronically implanted optic nerve visual prosthesis.

15 l agent for a neurotransmitter-based retinal prosthesis.

16 outcomes related to tissue versus nontissue prosthesis.

17 so enable an implant-borne dental or orbital prosthesis.

18 mental to the successful design of a retinal prosthesis.

19 gurations for use in an implantable epilepsy prosthesis.

20 sting hearing in animals with an implantable prosthesis.

21 for control of execution onset in a cortical prosthesis.

22 del, a prerequisite for a successful retinal prosthesis.

23 C can be used for direct control of a neural prosthesis.

24 at this technique may be useful for a visual prosthesis.

25 nee prostheses, and 1 patient with a femoral prosthesis.

26 he mechanical stimulation of a bone-anchored prosthesis.

27 thesis than among recipients of a mechanical prosthesis.

28 ients with a malfunctioning cobalt-alloy hip prosthesis.

29 ter implantation of this new artificial iris prosthesis.

30 ring valvuloplasty, and repositioning of the prosthesis.

31 ver been described in a patient with an iris prosthesis.

32 ve endophthalmitis in a patient with an iris prosthesis.

33 f 36) in subjects with an antimicrobial-free prosthesis.

34 y from 13 mechanical sensors embedded on the prosthesis.

35 nalyzed totaling 406 patients (Suture = 186, Prosthesis = 220).

36 maker implantation compared with the Edwards prosthesis (28.9% [95% CI: 23.0% to 36.0%] vs. 4.9% [95%

37 actures (4 patients, 2.5%), loosening of the prosthesis (3 patients, 1.9%), joint dislocation (2 pati

38 ck of elongation effect or shortening of the prosthesis (7 patients, 4.5%), prosthesis fractures (4 p

39 imultaneously optimizing human movements and prosthesis actuation, minimizing a weighted sum of human

40 ng provides patients with proper oculofacial prosthesis alignment and retention assisting in the reha

41 ther, in animals that had learned to use the prosthesis, altering the topographic mapping from IR sen

42 igher mortality than receipt of a mechanical prosthesis among patients 40 to 49 years of age (44.1% v

43 -year mortality than receipt of a mechanical prosthesis among patients 45 to 54 years of age (30.6% v

44 reas MRI metal artifacts may preclude direct prosthesis analysis, MRI provided information on PHV-rel

45 ir mandibular ramus was elongated by the TMJ prosthesis and 2 patients were combined with Le Fort I o

46 bjects with an antimicrobial-loaded cemented prosthesis and 58.3% (21 of 36) in subjects with an anti

47 view recent advances in optogenetics, visual prosthesis and electrostimulation to treat outer retinal

48 h as repositioning or retrieval of the valve prosthesis and embolization of the prosthesis; and other

49 treating these complications, retaining the prosthesis and preserving useful vision.

50 temporal patterns of retinal activity with a prosthesis and that temporal multiplexing may aid in rep

51 especially the interaction between the valve prosthesis and the native aortic valve, may play a major

52 al delivery of a self-expanding mitral valve prosthesis and were examined in a prospective registry f

53 e PET/CT scan, location and size/type of the prosthesis, and location and extent of the disease.

54 ty, prolonged pain, midline deviation of the prosthesis, and prosthesis fracture.

55 calcified cusps, suboptimal placement of the prosthesis, and/or annulus-prosthesis-size mismatch due

56 the valve prosthesis and embolization of the prosthesis; and other complications.

57 I implant is the first-generation epiretinal prosthesis approved for an investigational clinical tria

58 The custom-made, flexible silicone iris prosthesis ArtificialIris (HumanOptics, Erlangen, German

59 pigmentosa were implanted with the Argus II prosthesis as part of a phase 1/2 feasibility study at m

60 enefit that was associated with a mechanical prosthesis, as compared with a biologic prosthesis, pers

61 ndidate for a neurotransmitter-based retinal prosthesis, as its local application effectively stimula

62 self image, providing the possibility that a prosthesis becomes not only a tool, but also an integrat

63 o guide bony mass removal and locate the TMJ prosthesis (Biomet, USA).

64 Medtronic CoreValve (Minneapolis, Minnesota) prosthesis by echocardiography, angiography, and measure

65 ting in order to improve the fixation of the prosthesis by forming a bony connection to the remainder

66 Operant control of a prosthesis by neuronal cortical activity is one of the s

67 imulations of an amputee using an ankle-foot prosthesis by simultaneously optimizing human movements

68 Use of an epiretinal visual prosthesis can allow RP patients with no more than bare

69 antation for dysfunctional biological mitral prosthesis can be performed with minimal operative morbi

70 king with an appropriately optimized robotic prosthesis can have a lower metabolic cost--even lower t

71 The balloon-expandable ES prosthesis caused significantly more HITS (mean [95% CI]

72 Patient and prosthesis characteristics, lead type, and clinical even

73 ional results following implantation of iris prosthesis combined with cataract surgery in eyes with p

74 -effectiveness of TAVR with a self-expanding prosthesis compared with surgical aortic valve replaceme

75 d human subjects with a prototype epiretinal prosthesis consisting of a 4 x 4 array of 16 stimulating

76 vel approach of motor neuron interfacing for prosthesis control and provide new insights into the rol

77 cles and skin, creating nerve interfaces for prosthesis control and sensory feedback.

78 signing physiologically inspired methods for prosthesis control.

79 s additional recording sites for myoelectric prosthesis control.

80 mizing a weighted sum of human metabolic and prosthesis costs.

81 ine interface (BMI) that controls a grasping prosthesis could be realized by detecting the time of gr

82 imulation of canal afferents by a vestibular prosthesis could potentially improve vestibular percepts

83 ealing, stage II to prosthesis delivery, and prosthesis delivery to up to 10 years of follow-up.

84 to stage I to stage II healing, stage II to prosthesis delivery, and prosthesis delivery to up to 10

85 ere was one failure from stage II healing to prosthesis delivery.

86 diction of appropriate projection angles for prosthesis deployment.

87 disease (OR, 6.36; 95% CI, 1.56-25.87), and prosthesis depth (in millimeters) (OR, 1.31; 95% CI, 1.0

88 arger aortic annulus (P=0.0004), and smaller prosthesis diameter (P=0.0001).

89 Aortic annulus and prosthesis diameter were not predictors of postprocedura

90 microelectrodes in cerebral cortex, a neural prosthesis discriminated action potentials (spikes) in p

91 cterial infection or the displacement of the prosthesis due to insufficient fixation.

92 131.6]; P<0.001) and the self-expandable MCV prosthesis during implantation (MCV(TF), 397.1 [302.1-49

93 atory testing could add value in quantifying prosthesis dysfunction and could suggest a pathophysiolo

94 ng was noted in 6 of 24 patients with aortic prosthesis dysfunction and in 5 of 19 patients with mitr

95 timers are associated with aortic and mitral prosthesis dysfunction, with occasional gastrointestinal

96 olism and may identify a reversible cause of prosthesis dysfunction.

97 to optimal solutions predict that increasing prosthesis energy cost, decreasing prosthesis mass, and

98 provides compelling evidence that the neural prosthesis enhanced functional connectivity between the

99 crease in the use of mechanical mitral valve prosthesis even in the younger population.

100 The use of an electronic retinal prosthesis facilitates reach-and-grasp performance.

101 eolysis and the loss of fixation in a murine prosthesis failure model.

102 regurgitation and transcatheter aortic valve prosthesis failure seems to be safe, and it is associate

103 However, early placement of a penile prosthesis following radical prostatectomy is now a prov

104 ied the capabilities of the Argus II retinal prosthesis for guiding fine hand movement, and demonstra

105 nt dislocation (2 patients, 1.3%), stump and prosthesis fracture (1 patient, 0.6%) and local recurren

106 in, midline deviation of the prosthesis, and prosthesis fracture.

107 tening of the prosthesis (7 patients, 4.5%), prosthesis fractures (4 patients, 2.5%), crural fracture

108 ological (n=24 410) or mechanical (n=14 789) prosthesis from 1991 to 1999 at 605 centers within the S

109 tentials can be used to examine how a visual prosthesis generates visual sensations.

110 major bleeding was higher in the mechanical prosthesis group (13.0% [95% CI, 9.9%-16.1%] vs 6.6% [95

111 2.1% (95% CI, 58.2%-66.0%) in the mechanical prosthesis group (hazard ratio, 0.97 [95% CI, 0.83-1.14]

112 8.6% (95% CI, 6.2%-11.0%) in the mechanical prosthesis group (hazard ratio, 1.04 [95% CI, 0.75-1.43)

113 e of reoperation was lower in the mechanical prosthesis group compared with the bioprosthesis group.

114 Although compliance (visco-elasticity) of a prosthesis has the potential to affect clinically releva

115 ard ratio, 4.0 [1.5-11]), implantation of >1 prosthesis (hazard ratio, 5.2 [1.5-18]), and any vascula

116 the limitations of currently available valve prosthesis, heart valve tissue engineering has emerged a

117 er rGSN than the best commercially available prosthesis; however, this is unlikely to be the global o

118 has potential as a new site for an auditory prosthesis [i.e., auditory midbrain implant (AMI)] for d

119 hin their home and community using a passive prosthesis (ie, one that does not provide external power

120 Other variables, such as type of prosthesis, implant surface, and timing of prosthetic lo

121 ic valve replacement (AVR) allows for larger prosthesis implantation and may be an important adjunct

122 n the context of traumatic aniridia and iris prosthesis implantation due to other potential etiologie

123 esholds in patients about to undergo retinal prosthesis implantation.

124 with retinitis pigmentosa undergoing retinal prosthesis implantation.

125 e RP (implanted with a 16-channel epiretinal prosthesis in 2004) on nine individual electrodes.

126 and older continued to receive a mechanical prosthesis in 2011.

127 implantation of a novel magnetic oculomotor prosthesis in a patient.

128 ve replacement with a mechanical or biologic prosthesis in California in the period from 1996 through

129 lvular replacement surgery and the choice of prosthesis in dialysis patients with bacterial endocardi

130 allow safe placement of a three-piece penile prosthesis in patients with a history of pelvic surgery.

131 gical TV replacement with a biological valve prosthesis in patients with congenital heart disease.

132 er of successful grasps was greater with the prosthesis in the 'On' setting (visit 1: median [interqu

133 ck up a high-contrast cuboid object with the prosthesis in the 'On', 'Off' or 'Scrambled' setting pre

134 ly developed a wireless photovoltaic retinal prosthesis, in which camera-captured images are projecte

135 n predilatation, use of the larger CoreValve prosthesis, increased interventricular septum diameter a

136 e, peripheral arterial disease, and a deeper prosthesis insertion are associated with myocardial inju

137 Two implants were lost within 2 months after prosthesis insertion in two patients, with an overall su

138 l implant placement and immediate definitive prosthesis installation.

139 ematics, here, we explicitly model the human-prosthesis interaction to produce a prediction of the us

140 to the unintended implantation of a revision prosthesis into an infected surgical site with the risk

141 TMJ reconstruction with standard alloplastic prosthesis is a reliable treatment for ankylosis, especi

142 Movement of the myoelectric prosthesis is enabled via decoded electromyography activ

143 seem, however, still functional, even if the prosthesis is implanted in the peripheral retina.

144 the best available studies to determine what prosthesis is most appropriate when valve replacement is

145 replacement, either a mechanical or biologic prosthesis is used.

146 th specimens from patients with septic joint prosthesis loosening (septic total arthroplasty [SeTA];

147 n preoperatively distinguish between aseptic prosthesis loosening and low-grade joint infection, and

148 approach in differentiating between aseptic prosthesis loosening and low-grade joint infection.

149 There was no prosthesis loosening, breakage, or infection leading to

150 is [bio-CVG], n = 180; CVG with a mechanical prosthesis [m-CVG], n = 183).

151 ncreasing prosthesis energy cost, decreasing prosthesis mass, and allowing asymmetric gaits all decre

152 uccessful, surgical implantation of a penile prosthesis may be considered.

153 of retinal neurons with an advanced retinal prosthesis may eventually provide high-resolution artifi

154 wered prosthesis) responds to changes in the prosthesis mechanics and gravitational load.

155 heter implanted self-expandable aortic valve prosthesis (Medtronic CoreValve).

156 The subclavian approach with the CoreValve prosthesis (Medtronic, Inc., Minneapolis, Minnesota) rep

157 3 patients underwent TAVI with the CoreValve prosthesis (Medtronic, Minneapolis, Minnesota) at 14 cen

158 radient, larger valve area, and less patient-prosthesis mismatch (all P<0.001), but more paravalvular

159 in small surgical valves because of patient/prosthesis mismatch.

160 nt aortic valve replacement with a Mitroflow prosthesis (models 12A/LX) between 2002 and 2007.

161 ccurately represent a visual scene, a visual prosthesis must convey luminance information across a ra

162 n = 3) osteomyelitis (n = 2), infected joint prosthesis (n = 2), and peritonitis (n = 2) being the mo

163 radiographs of patients with an aortic valve prosthesis (n = 473) were analyzed to determine the loca

164 ot (n=78) or a mechanically valved composite prosthesis (n=127) between February 1998 and July 2011.

165 To function successfully, a retinal prosthesis needs to provide effective stimulation in a s

166 dental implants, who had neither a metallic prosthesis nor metal restorations in neighboring teeth.

167 CVEs were balloon postdilation of the valve prosthesis (odds ratio, 2.46; 95% confidence interval,1.

168 o 3.47), use of the larger (29 mm) CoreValve prosthesis (odds ratio, 2.50; 95% confidence interval, 1

169 pment of a neurotransmitter-based subretinal prosthesis offering more naturalistic vision and better

170 onfidence interval, 3.23-36.91; P<0.001) and prosthesis oversizing >/=20% (odds ratio, 8.38; 95% conf

171 the S3-THV, despite reduced annulus area to prosthesis oversizing (8.2+/-5.1 versus 18.2+/-10.7%, P=

172 on-expandable TAVI is associated with severe prosthesis oversizing.

173 th IFS was similar close to and far from the prosthesis (P = .295).

174 ion (p = 0.037) and ventricular depth of the prosthesis (p = 0.017) were independent predictors of pe

175 replacement had a lower incidence of severe prosthesis-patient mismatch (19.7% versus 37.5%; P=0.03)

176 2)/m(2); P=0.003), and lower rates of severe prosthesis-patient mismatch (3% versus 22%; P=0.004).

177 longer cardiopulmonary bypass duration, and prosthesis-patient mismatch (indexed effective orifice a

178 lted in larger indexed EOA (p = 0.038), less prosthesis-patient mismatch (p = 0.019), and more total

179 Furthermore, prosthesis-patient mismatch (PPM) after aortic valve rep

180 Little is known about the incidence of prosthesis-patient mismatch (PPM) and its impact on outc

181 The prevalence of prosthesis-patient mismatch (PPM) and its impact on surv

182 Prosthesis-patient mismatch (PPM) may hinder normalizati

183 nging because they are at increased risk for prosthesis-patient mismatch and impaired outcomes.

184 le, there were no differences in the rate of prosthesis-patient mismatch between groups, and a signif

185 access cohort, there were no differences in prosthesis-patient mismatch between the small aortic ann

186 ransvalvular gradients and consequently less prosthesis-patient mismatch compared with the SAPIEN 3 i

187 volumes, low stroke volume, smaller EOA, and prosthesis-patient mismatch in SAVR patients.

188 Severe prosthesis-patient mismatch was defined as an effective

189 TAVR patients had higher indexed EOA, lower prosthesis-patient mismatch, and more aortic regurgitati

190 Incomplete LV recovery, prosthesis-patient mismatch, low transaortic valve press

191 The concept/phenomenon of valve prosthesis/patient mismatch (VP-PM), described in 1978,

192 ical prosthesis, as compared with a biologic prosthesis, persisted until 70 years of age among patien

193 mm of bone loss occurred between the time of prosthesis placement and 1-year postloading.

194 ween the time of implant placement and final prosthesis placement around one-stage non-submerged tita

195 fter prosthesis placement, and annually from prosthesis placement for 5 years.

196 Penile prosthesis placement results in early return to sexual f

197 inal prosthesis placement, at 6 months after prosthesis placement, and annually from prosthesis place

198 radiographs were taken at the time of final prosthesis placement, at 6 months after prosthesis place

199 melanoma, combined cataract surgery and iris prosthesis placement, with or without iris reconstructio

200 of 5 years was accounted for at the time of prosthesis placement.

201 with BPVT were matched 1:2 for age, sex, and prosthesis position with patients whose valves were expl

202 However, suboptimal prosthesis positioning may contribute to paravalvular re

203 ntation of procedural success, evaluation of prosthesis positioning, and identification of asymptomat

204 tanium-encased, rare-earth magnet oculomotor prosthesis, powered to damp nystagmus without interferin

205 stance from the postdeployment perpendicular prosthesis projection to the regression line of predicte

206 same control system to operate advanced arm prosthesis prototypes.

207 trial population, TAVR with a self-expanding prosthesis provided meaningful clinical benefits compare

208 Increased prosthesis push-off significantly reduced metabolic ener

209 imental test of this idea wherein ankle-foot prosthesis push-off work was incrementally varied in iso

210 Prosthesis recapture and repositioning was performed in

211 selected third-generation mechanical aortic prosthesis recipients, low-dose anticoagulation therapy

212 rence in the rate of cardiovascular death or prosthesis reintervention was found.

213 racing time increased by 156% when using the prosthesis, relative to residual vision.

214 Subjects with frequent prosthesis removal had a significantly (P = .02) greater

215 relapse, death, need for salvage therapy, or prosthesis removal occurred.

216 e found in subjects with higher frequency of prosthesis removal.

217 function and in 5 of 19 patients with mitral prosthesis/repair dysfunction and was associated with a

218 therapy; 3 of these patients later underwent prosthesis replacement with sustained recovery.

219 Eighteen patients (50%) underwent prosthesis replacement; all were successful after median

220 reated with debridement and retention of the prosthesis, resection arthroplasty with or without subse

221 hought about using her hand or elbow and the prosthesis responded appropriately.

222 ed how each system (i.e. amputee and powered prosthesis) responds to changes in the prosthesis mechan

223 r implant (CI) is the most successful neural prosthesis, restoring the sensation of sound in people w

224 ansfemoral TAVI with the self-expandable MCV prosthesis resulted in the greatest number of HITS, pred

225 there is no association between the type of prosthesis retention and peri-implant diseases.

226 the role of osseointegration for oculofacial prosthesis retention in patients requiring orbital exent

227 er their patients an adhesive-free method of prosthesis retention.

228 tions, using a carbon fibre running-specific prosthesis (RSP).

229 onically implanted with the Argus II retinal prosthesis (Second Sight Medical Products, Inc., Sylmar,

230 omes in left-sided endocarditis based on the prosthesis selected for implantation are limited and no

231 These results emphasize the need of careful prosthesis selection in each individual patient.

232 Valve procedure and valve prosthesis selection when replacement is indicated can p

233 brain injury can be facilitated by a neural prosthesis serving as a communication link between dista

234 Ultimately, the choice of prosthesis should be made after careful discussion with

235 in-computer interface system using an online prosthesis simulator, a simple human-in-the-loop pyschop

236 Mean prosthesis size implanted was slightly smaller in patien

237 rence-derived cross-sectional diameter minus prosthesis size] of 0.81 (95% confidence interval: 0.7 t

238 for [maximal cross-sectional diameter minus prosthesis size] of 0.82 (95% confidence interval: 0.69

239 placement of the prosthesis, and/or annulus-prosthesis-size mismatch due to malsizing can contribute

240 of paravalvular regurgitation, compared with prosthesis sizing with two-dimensional echocardiography.

241 Patient selection, prosthesis sizing, and access strategies heavily rely on

242 supporting appropriate patient selection and prosthesis sizing.

243 operative cultures were negative, but PCR of prosthesis sonicate fluid was positive, as was stool cul

244 PCR of prosthesis sonication samples is more sensitive than tis

245 eless fashion using oversizing to anchor the prosthesis stent frame at the level of the virtual aorti

246 Marginal bone loss (BL) and implant and prosthesis survival rates were calculated.

247 ost-effectiveness of the Argus(R) II Retinal Prosthesis System (Argus II) in Retinitis Pigmentosa (RP

248 The Argus II Retinal Prosthesis System (Second Sight Medical Products, Inc, S

249 ability, and benefit of the Argus II Retinal Prosthesis System (Second Sight Medical Products, Inc, S

250 This study evaluated the Argus II Retinal Prosthesis System (Second Sight Medical Products, Inc.,

251 s on the development of the Argus II retinal prosthesis system (Second Sight Medical Products, Inc.,

252 erm safety results of Second Sight's retinal prosthesis system are acceptable, and most subjects with

253 Products Inc. developed Argus II, a retinal prosthesis system for treating RP.

254 e collective experiences of Argus II Retinal Prosthesis System investigators to review strategies to

255 flatscreen monitor in 3 conditions: with the prosthesis system on and a 1-to-1 mapping of spatial inf

256 orm the task significantly better with their prosthesis system than they were with their residual vis

257 After the Argus II Retinal Prosthesis System was implanted, complications and anato

258 Implantation of the Argus II Retinal Prosthesis System was safely performed in all patients.

259 dvancements in three-piece inflatable penile prosthesis technology of interest to surgeons who implan

260 cantly higher among recipients of a biologic prosthesis than among recipients of a mechanical prosthe

261 r implants are the first example of a neural prosthesis that can substitute a sensory organ: they byp

262 d test a target-based cortical-spinal neural prosthesis that employs neural activity recorded from pr

263 siderable evidence that a semicircular canal prosthesis that senses angular head velocity and stimula

264 ould serve as a line of communication from a prosthesis to cortical hand processing regions.

265 e regarding the potential utility of a canal prosthesis to improve perceptual deficits.

266 m and combined with data from sensors on the prosthesis to interpret the patient's intended movements

267 Prosthesis use decreased error by 38% and increased trac

268 Medtronic CoreValve prosthesis use was associated with a significant higher

269 promises to improve assessment of real world prosthesis use, leading to a better matching of prosthes

270 e quality of vascular access and the type of prosthesis used.

271 including definition of the type of ring or prosthesis used; description of the site, size, shape, a

272 geted reinnervation could be used to provide prosthesis users with a sense of touch.

273 oved environment perception of bone-anchored prosthesis users.

274 tegy consisted of precise positioning of the prosthesis using a modified TAVI technique and immediate

275 d in animals an alternative mode of auditory prosthesis using penetrating auditory-nerve electrodes t

276 ne of predicted angles to the postdeployment prosthesis view was 5.1+/-4.6 degrees for 3DA and 7.9+/-

277 angle, and the postdeployment perpendicular prosthesis view were compared.

278 often report a social stigma associated with prosthesis visibility.

279 y showed that culture of samples obtained by prosthesis vortexing and sonication was more sensitive t

280 The overall retention rate of the initial prosthesis was 77%.

281 f transapical TAVI with a balloon-expandable prosthesis was associated with a low incidence of releva

282 tic-valve replacement, receipt of a biologic prosthesis was associated with significantly higher 15-y

283 ral-valve replacement, receipt of a biologic prosthesis was associated with significantly higher mort

284 Early hemodynamic performance of the prosthesis was excellent.

285 r more than 2 post-operative years, the iris prosthesis was explanted, and intravitreal cultures show

286 Although the first inflatable penile prosthesis was introduced over 30 years ago for the trea

287 Type of prosthesis was unrelated to mortality.

288 VI CAAD and nominal diameter of the selected prosthesis, was 9.8%+/-7.8%.

289 were 50 subjects (mean age: 31.3 years, mean prosthesis wear: 96.1 months).

290 A superior implant locus may help the prosthesis wearer better control horizontal eye movement

291 subjects implanted with the Argus II retinal prosthesis were able to perform a motion detection task

292 on and a more ventricular positioning of the prosthesis were associated with a higher rate of persist

293 n TAVR registry with CoreValve and Sapien-XT prosthesis were compared according to the implantation t

294 (n=22) or self-expandable (n=10) stent valve prosthesis were included in this descriptive study and c

295 l acuity in human users of a future auditory prosthesis, which in turn might improve musical pitch pe

296 (i.e. weighted backpack) and a powered knee prosthesis with two pre-programmed controller settings (

297 (performed with the use of a self-expanding prosthesis) with surgical aortic-valve replacement.

298 jects (>/=6 years and >/=6 months of wearing prosthesis) with unilateral acquired anophthalmic socket

299 expenditure, with a 14% reduction at maximum prosthesis work.

300 that culturing of samples obtained from the prosthesis would improve the microbiologic diagnosis of